CURRICULUM VITAE Date Prepared: October 9, 2007 · CURRICULUM VITAE Date Prepared: October 9, 2007 Name : David Reardon, MD Primary academic appointment: Department of Pediatrics

CURRICULUM VITAE

Date Prepared: October 9, 2007

Name : David Reardon, MD

Primary academic appointment: Department of Pediatrics

Primary academic department: Department of Surgery

Secondary appointment: Department of Surgery

Present academic rank and title: Associate Professor of Pediatrics Associate Professor in Surgery

Date and rank of first Duke Faculty appointment: 08/15/2000

Medical Licensure: North Carolina License Date of License (October 10, 2000)

Specialty certification(s) and dates: Board Certified in Pediatric Hematology-Oncology, American Board of Pediatrics (certified 11/15/94, recertified 5/24/00).

Date of birth: September 3, 1960 Place : Norwood, MA

Citizen of: United States Visa status

Education

Institution Date Degree

High School Xaverian Brothers Westwood MA

1978 Diploma

College Cornell University Ithaca, NY

1982 BA

Graduate or Professional School

Tufts University School of Medicine, Boston, MA

1986 MD

Name: David A. Reardon, MD Date: October 9, 2007

2

Scholarly societies:

Professional training and academic career:

Institution Position/Title Dates Johns Hopkins Hospital Baltimore, MD

Internship 1986-97

Johns Hopkins Hospital Baltimore, MD

Residency 1987-89

University of Michigan Hospital Mott Children’s Hospital Ann Arbor, MI

Fellowship 1989-92

University of Michigan Hospital Ann Arbor, MI

Attending Physician (Part-time) 1989-92

Naval Medical San Diego San Diego, CA

Staff Physician 1992-95

University of Tennessee Memphis, TN

Assistant Professor 1995-98

St. Jude Children’s Research Hospital Memphis, TN

Assistant Member 1995-98

Maine Children’s Cancer Program Portland, ME

Staff Physician 1998-2000

University of Vermont School of Medicine

Associate Professor 1998-2000

Duke University Medical Center Durham, NC

Assistant Professor 2000-2002

Duke University Medical Center Durham, NC

Associate Professor 2003-present


3

Publications:

Refereed journals:

1. Reardon, DA, Roskos, R, Hanson, CA, Castle, V. Virus-associated hemophagocytic syndrome (VAHS)

following bone marrow transplantation (BMT). Am J Pediatr Hematol Oncol 13:305-309, 1991. 2. Adams, PT, Robertson, RD, Reardon, DA, Roth, MS. Detection of circulating donor white blood cells in

patients receiving multiple transfusions. Blood 80:1-4, 1992. 3. Reardon, DA, Castle, V, Hanson, CA, Roth, MS. Lineage-switch in Philadelphia chromosome-positive

(Ph+) pediatric acute leukemia. Cancer 73:1526-1532, 1994. 4. Reardon, D, Michalkiewicz, E, Boyett, J, Sublett, J, Entrekin, R, Ragsdale, S, Valentine, M, Behm, F, Li,

H, Heideman, R, Kun, L, Shapiro, D, Look, A. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridzation. Cancer Res 57:4042-4047, 1997.

5. Hutchinson, RJ, Fryer, CJH, Davis, PC, Nachman, J, Krailo, MD, O’Brien, RT, Collins, RD, Whalen, T,

Reardon, D, Trigg, ME, Gilchrist, GS. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin’s disease in children: Results of the Children’s Cancer Group phase III trial. J Clin Oncol 16:897-906, 1998.

6. Reardon, D, Gajjar, A, Sanford, R, Heideman, R, Walter, A, Thompson, S, Boyett, J, Li, H, Jenkins, J,

Langston, J, Kun, L. Bithalamic involvement predicts a poor outcome among children with thalamic glial tumors. Pedatr Neurosurg 29:29-35, 1998.

7. Sublett, J, Entrekin, E, Look, A, Reardon, D. Chromosomal localization of the human smoothened gene

(SMOH) to 7q32.3 by fluorescence in situ hybridzation and radiation hybrid mapping. Genomics 50:112-114, 1998.

8. Chow, E, Merchant, T, Shah, A, Reardon, D, Jenkins, J, Langton, J, Heideman, R, Sanford, R, Kun, L.

Malignant evolution of choroid plexus papilloma. Pediatr Neurosurg 31:127-130, 1999. 9. Chow, E, Reardon, D, Shah, A, Jenkins, J, Langston, J, Heideman, R, Sanford, R, Kun, L, Merchant, T.

Pediatric choroid plexus neoplasms. Int J Rad Onc Biol Phys 44:249-254, 1999. 10. Gajjar, A, Fouladi, M, Walter, A, Thompson, S, Reardon, D, Merchant, T, Jenkins, J, Liu, A, Boyett, J,

Kun, L, Heideman, R. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncology 17:1825-1828, 1999.

11. Merchant, TE, Nguyen, D, Thompson, SJ, Reardon, DA, Kun, LE, Sanford, RA. High-grade pediatric

spinal cord tumors. Pediatr Neurosurg 30(1):105, 1999. 12. Reardon, D, Entrekin, B, Sublett, J, Ragsdale, S, Li, H, Boyett, J, Look, A. Chromosome 6q loss is the

most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes, Chromosomes Cancer 24:230-237, 1999.


4

13. Walter, A, Mulhern, R, Gajjar, A, Heideman, R, Reardon, D, Sanford, A, Xiong, X, Li, H, Kun, L.

Survival and neurodevelopment outcome of young children with medulloblastoma at St. Jude Children’s Research Hospital. J Clin Oncol 17:3720-3728, 1999.

14. Dong, J, Gailani, M, Pomeroy, S, Reardon, D, Bale, A: Identification of PATCHED mutations in

medulloblastomas by direct sequencing. Human Mutation, Mutation in Brief #339 (2000) Online. 15. Reardon, DA, Sublett, JE, Ragsdale, ST, Jenkins, JE, Thompson, S, Merchant, T, Kun, LE, Burger, PC.

Multiple genomic alterations including N-myc amplification in a primary large-cell medulloblastoma. Pediatr Neurosurg 32:187-191, 2000.

16. Walter, AW, Gajjar, A, Reardon, D, Thompson, S, Langston, J, Jones-Wallace, D, Kun, LE, Heideman,

R, Tamoxifen, Carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children’s Research Hospital. Pediatr Hematol Oncol 22:247-251, 2000.

17. Gururangan, S, Cavazos, CM, Herndon II, JE, Ashley, D, Bruggers, C., Moghrabi, A., Watral, M., Tourt-

Uhlig, S., Reardon, D., and Friedman, H.S.: A Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin. Oncol., 20:2951-2958, 2002.

18. Quinn, JA, Pluda, J, Dolan, ME, Delaney, S, Kaplan, R, Rich, JN, Friedman, AH, Reardon, DA,

Sampson, JH, Colvin, OM, Haglund, MM, Pegg, AE, Moschel, RC, McLendon, RE, Provenzale, JM, Gururangan, S, Tourt-Uhlig, S, Herndon II, JE, Bigner, DD, Friedman, HS. Phase 2 trial of carmustine plus O6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol, 20(9):2277-2283, 2002.

19. Reardon, DA, Akabani, G, Coleman, RE, Friedman, AH, Friedman, HS, Herndon II, JE, Cokgor, I,

McLendon, RE, Pegram, CN, Provenzale, JM, Quinn, JA, Rich, J, Regalado, LV, Sampson, JH, Shafman, TD, Wikstrand, CJ, Wong, TZ, Zhao, X-G, Zalutsky, MR, Bigner, DD. Phase II trial results of murine 131I-labeled anti-tenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol, 20(5):1389-1397, 2002.

20. Gururangan, S, McLaughlin, C, Quinn, J, Rich, J, Reardon, D, Halperin, EC, Herndon II, J , Fuchs, H,

George, T, Provenzale, J, Watral, M, McLendon, RE, Friedman, A, Friedman, HS, Kurtzberg, J, Vredenbergh, J, Martin, PL. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol, 21(11):2187-2191, 2003.

21. Korones, D, Benita-Weiss, M, Coyle, T, Mechtler, L, Bushunow, P, Evans, B, Reardon, D, Quinn, J,

Friedman, H. Phase I Study of Temozolomide and Escalating Doses of Oral VP-16 for Adults with Recurrent Malignant Glioma. Cancer, 97(8):1963-8, 2003.

22. Quinn, JA, Reardon, DA, Friedman, AH, Rich, JN, Sampson, JH, Rovenzale, JM, McLendon, RE,

Gururangan, S, Bigner, DD, Herndon II, JE, Avgeropoulos, N, Finlay, J, Tourt-Uhlig, S, Affronti, ML, Evans, B, Stafford-Fox, V, Zaknoen, S., Friedman, HS. Phase II trial of temozolomide in partients with progressive low-grade glioma. J Clin Oncol, 21(4):646-651, 2003.


5

23. Sampson, J, Akabani, G, Archer, GE, Bigner, DD, Berger, MS, Friedman, AH, Friedman, HS, Herndon II, JE , Kunwar, S, Marcus, S, McLendon, RE, Paolion, A, Penne, K, Provenzale, J, Quinn, J, Reardon, DA, Rich, J, Stenzel, T, Tourt-Uhlig, S. Progress report of a Phase I study of the intracerebral micoinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Neuro-Oncology (1)65:27-35, 2003.

24. Badruddoja, MA, Vredenburgh, J, Peery, TS, Reardon, DA. Kluver-Bucy syndrome related to glioma.

Neurology 63(1):184, 2004. 25. Quinn, JA, Reardon, DA, Friedman, AH, Rich, JN, Sampson, JH, Vredenburgh, JJ, Gururangan, S,

Provenzale, JM, Walker, A, Schweitzer, H, Bigner, DD, Tourt-Uhlig, S, Herndon, II, JE, Affronti, ML, Jackson, S, Allen, DH, Zeigler, K, Bohlin, C, Lentz, C, and Friedman, HS. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-Oncology, 6(2):145-153, 2004.

26. Reardon, DA, Quinn, JA, Rich, JN, Gururangan, S, Vredenburgh, J, Sampson, JH, Provenzale, JM,

Walker, A, Perry, T, Badruddoja, M, Tourt-Uhlig, S, Herndon, JE, II, Dowell, JM, Affronti, ML, Jackson, S, Allen, D, Ziegler, K, Friedman, AH, Bigner, DD, Friedman, HS. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-Oncology, 6(2):134-144, 2004.

27. Rich, JN, Reardon, DA, Peery T, Dowsell, JM, Quinn, JA, Penne, KL, Wikstrand, CJ, Van Duyn, LB,

Dancey, JE, McLendon, RE, Kao, JC, Stenzel, TT, Rasheed, BKA, Tourt-Uhlig, SE, Herndon, II, JE, Vredenburgh, JJ, Sampson, JH, Friedman, AH, Bigner, DD, Friedman, HS. Phase II Trial of Gefitinib in Recurrent Glioblastoma. J Clin Oncol, 22(1):133-42, 2004.

28. Reardon, DA, Quinn, JA, Vredenbugh, JJ, Rich, JN, Gururangan, S, Badruddoja, M, Herndon, II, JE,

Dowell, JM, Friedman, AH, Friedman, HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 103(2):329-338, 2005.

29. Reardon, DA, Egorin, MJ, Quinn, JA, Rich, JN, Gururangan, S, Vredenburgh, JJ, Desjardins, A,

Sathornsumetee, S, Provenzale, JM, Tourt-Uhlig, S, Herndon II, JE, Dowell, JM, McLendon, RE, Lagattuta, TF, Kicielinski, KP, Dresemann, G, Salvado, AJ, Friedman, AH, Friedman, HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. 23(36):9359-9368, 2005.

30. Sampson, JH, Reardon, DA, Friedman, AH, Friedman, HS, Coleman, RE, McLendon, RE, Pastan, I,

Bigner, DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro-Oncology, 7(1):90-6, 2005.

31. Reardon, DA, Quinn, JA, Rich, JN, Desjardins, A, Vredenburgh, J, Gururangan, S, Badruddoja, M,

McLendon, R, Provenzale, J, Herndon II, JE, Dowell, JM, Burkart, JL, Newton, HB, Friedman, AH, Friedman, HS. Phase 1 Trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 104(7):1478-1486, 2005.

32. Akabani, G, Reardon, DA, Coleman, RE, Wong, TZ, Metzler, SD, Bowsher, JE, Barboriak, DP,

Provenzale, JM, Greer, KL, Delong, D, Friedman, HS, Friedman, AH, Zhao, X-G, Pegram, CN,


6

McLendon, RE, Zalutsky, MR, Bigner, DD. Dosimetry and radiographic analysis of iodine-131-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: A phase II study. J. Nuclear Med. 46:1042-1051, 2005.

33. Goudar, RK, Shi,Q, Hjelmeland, MD, Keir, ST, McLendon, RE, Wikstrand, CJ, Reese, ED, Conrad, CA,

Traxler, P, Lane, HA, Reardon, DA, Cavenee, WK, Wang, XF, Bigner, DD, Friedman, HS, Rich, JN. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of repamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 4(1):101-12, 2005.

34. McLendon, RE, Herndon II, JE, West, B, Reardon, DA, Wiltshire, R, Rasheed, BKA, Quinn, JA,

Friedman, HS, Friedman, AH, Bigner, DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 104(8):1693-99, 2005.

35. Quinn, JA, Desjardins A, Weingart J, Brem H, Dolan, ME, Delaney, SM, Vredenburgh, JJ, Rich, J,

Friedman AH, Reardon, DA, Sampson, JH, Pegg, AE, Moschel, RC, Birch, McLendon, RE, Provenzale, JM, Gururangan, S, Dancey, JE, Maxwell, J, Tourt-Uhlig, S, Herndon II, JE, Bigner, DD, Friedman, HS. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive. J Clin Onco, 23(28):7178-7187, 2005.

36. Rich, JN, Sathornsumetee, S, Keir, ST, Kieran, M, Laforme, A, McLendon, RE, Graner, MW, Reardon,

D, Wheeler, C, Dimery, I, Bigner, DD, and Friedman, HS. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple central nervous system tumors. Clin. Cancer Res. 11:8145-8157, 2005.

37. Desjardins, A, Rich, JN, Quin, JA, Vredenburgh, J, Gururangan, S, Sathornsumetee, S, Reardon, DA,

Friedman, AH, Bigner, DD, Friedman, HS. Chemotherapy and novel therapeutic approaches in malignant glioma. Frontiers in Bioscience, 10:2645-68, 2005.

38. Reardon, DA, Quinn, JA, Vredenburgh, JJ, Gururangan, S, Friedman, AH, Desjardins, A,

Sathornsumetee, S, Herndon II, JE, Dowell, JM, McLendon, RE, Provenzale, JM, Sampson, JH, Smith, RP, Swaisland, AJ, Ochs, JS, Lyons, P, Tourt-Uhlig, S, Bigner, DD, Friedman, HS, Rich,, JN. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Ca Res, 12(3):860-868, 2006.

39. Reardon, DA, Akabani, G, Coleman RE, Friedman, AH, Friedman, HS, Herndon II, JE, McLendon, RE,

Pegram, CN, Provenzale, JM, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Guruangan, S, Badruddoja, M, Dowell, JM, Wong, TZ, Zhao X, Zalutsky, MR, Bigner DD. Salvage Radioimmunotherapy with Murine 131I-Labeled Anti-Tenascin Monoclonal Antibody 81C6 for Patients with Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results. J Clin Onc, 24(1):115-122, 2006.

40. Reardon, DA, Rich, JN, Friedman, HS, Bigner, DD. Recent advances in the treatment of malignant

astrocytoma. J Clin Onc, 24(8):1-13, 2006. 41. Reardon, DA. Glioblastoma – more questions than answers? Nature Clin Practice, 3(2):60-61, 2006.


7

42. Reardon, DA, Wen, PY. Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. The Oncologist, 11:152-164, 2006.

43. Gururangan S, Brashears J, Watral MA, McLaughlin CA, Provenzale J, Coleman RE, Halperin EC,

Quinn J, Reardon D, Vredenburgh J, Friedman A, Friedman HS. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol; 77 (2):207-212, 2006.

44. Herndon II, JE, Reardon, DA, Graner, MW, Riggins, GJ, Wikstrand, CJ, Bigner, DD. Glycoprotein

nonmetastatic melanoma protein, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Can Res, 12(7):1970-1982, 2006.

45. Jones, LW, Guill, B, Keir, ST, Carter, K, Friedman, HS, Bigner, DD, and Reardon, DA. Patterns of

exercise across the cancer trajectory in brain tumor patients: a population-based survey. Cancer, 106(10):2224-32, 2006.

46. Reardon, DA, Quinn, JA, Akabani, G, Coleman, RE, Friedman, AH, Friedman, HS, Herndon II, JE,

McLendon, RE, Pegram, CN, Provenzale, JM, Dowell, JM, Rich, JN, Vredenburgh, JJ, Desjardins, A, Sampson, JH, Gururangan, S, Wong TZ, Badruddoja, MA, Zhao, XG, Bigner, DD, Zalutsky, MR. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolableled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med, 47(6):912-918, 2006.

47. Kuan, C, Wakiya, K, Dowell, JM, Hernson II, JE, Reardon, DA, Graner, MW, Riggins, GJ, Wikstrand,

CJ, Bigner, DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Can Res, 12 7 Pt1):1970-1982, 2006.

48. Sathornsumetee, S, Keir, S, Kieran, M, Batt, D, Reardon, D, and Bigner, DD, Friedman, HS, and Rich,

JN: AAL881, a novel small molecule inhibitor of RAF and VEGFR activities, blocks growth of malignant gliomas. Cancer Res, 66(17):8722-30, 2006.

49. Desjardins, A , Quinn, JA, Vredenburgh, JJ, Sathornsumetee, S, Friedman, AH, Herndon, JE, McLendon,

RE, Provenzale, JM, Rich, JN, Sampson, JH, Gururangan, S, Dowell, JM, Salvado, A, Friedman, HS, Reardon, DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 83(1):53-60, 2007.

50. Yamamoto, Y, Wong, TZ, Turkington, TG, Hawk, TC, Reardon, DA, Coleman RE. 3’-Deoxy-3’-[F-

18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparision with Gd-DTPA enhanced magnetic resonance imaging. Molecular Imaging & Biology 8(6):340-7, 2006.

51. Jones, LW, Guill, B, Keir, ST, Carter, K, Friedman, HS, Bigner, DD, and Reardon, DA: Exercise interest

and preferences among patients diagnosed with primary brain cancer. Supportive Care in Cancer, 15(1):47-55, 2007.

52. Badruddoja, MA, Penne, K, Desjardins, A, Reardon, DA, Rich, JN, Quinn, J, Sathornsumetee, S,

Friedman, AH, Bigner, DD, Herndon II, JE, Dowell, J, Sznol, M, Cahill, A, Friedman, HS, and Vredenburgh, JJ: Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol. 9(1):70-4, 2007.


8

53. Vredenburgh, JJ, Desjardins, A, Herndon, JE, Dowell, JM, Reardon, DA, Quinn, JA, Rich, JN,

Sathornsumetee, S, Gururangan, S, Wagner, M, Bigner, DD, Friedman, AH, Friedman, HS. Phase II trial of Bevacizumab and Irinotecan in recurrent malignant glioma. Clin Cancer Res. 13(4):1253-59, 2007.

54. Sampson, JH, Radhavan, R, Provenzale, JM, Croteau, D, Reardon, DA, Coleman, RE, Ponce, IR, Pastan,

I, Puri, RK, Pedain, C. Induction of hyperintense signal on T-2-weighted MR images correlates with infusion distribution from intracerebral convention-enhanced delivery of a tumor-targeted cytotoxin. Am J Roentgenology. 188(3): March, 703-9, 2007.

55. Jones LW, Guill B, Keir ST, Carter K, Friedman HS, Bigner DD, Reardon DA. Using the theory of

planned behavior to understand the determinants of exercise in patients diagnosed with primary brain cancer. Psycho-Oncology. 16(3):232-40, March 2007.

56. Gururangan, S, Fisher, MJ, Allen, JC, Herndon II, JE, Quinn, JA, Reardon, DA, Vredenburgh, JJ,

Desjardins, A, Phillips, PC, Watral, MA, Krauser, JM, Friedman, AH, Friedman, HS. Temozolomide in children with progressive low-grade glioma. Neuro-Oncol. 9(2):161-8, 2007.

57. Sathornsumetee S, Desjardins A, Reardon DA, Rich JN, Vredenburgh JJ. Neurofibromatosis type 2.

Neurology 68(13): E14, 2007.

58. Sathornsumetee, S, Reardon, DA, Desjardins, A, Quinn, JA, Vredenburgh, JJ, Rich, JN. Molecularly Targeted Therapy for Malignant Glioma. Cancer. 110(1):13-23, 2007.

59. Reardon, DA, Zalutsky, MR, Bigner, DD. Antitenascin-C monoclonal antibody radioimmunotherapy for

malignant glioma patients. Expert Rev Anticancer Ther 7(5):675-87, 2007.

60. McLendon, RE, Akabani, G, Friedman, HS, Reardon, DA, Cleveland, L, Cokgor, I, Herndon II, JE, Wikstrand, C, Boulton, ST, Friedman, AH, Bigner, DD, Zalutsky, MR. Tumor resection cavity administered iodine-131-lableed anti-tenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol. 34(4):406-13, 2007, 2007.

61. Bullitt, E, Reardon, DR, Smith, JK. A Review of Micro- and Macrovascular Analyses in the Assessment

of Tumor-Associated Vasculature as Visualized by MR. NeuroImage Suppl 1 37:S116-9, 2007.

62. Gururangan, S, Fisher, MJ, Allen, JC, Herndon II, JE, Quinn, JA, Reardon, DA, Vredenburgh, JJ, Desjardins, A, Phillips, PC, Watral, MA, Krauser, JM, Friedman, AH, Friedman, HS. Temozolomide in children with progressive low-grade glioma. Neuro-Oncol. 9(2):161-8, 2007.

63. Sampson, JH, Raghaven, R, Brady, ML, Provenzale, J, Herndon, JE, Croteau, D, Friedman, AH,

Reardon, DA, Coleman, RE, Wong T, Bigner, DD, Pastan, I, Rodrigues-Ponce, MI, Tanner, P, Puri, R, Pedain, C. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro-Oncol. 9(3):343-63, 2007.

64. Zalutsky, MR, Reardon, DR, Pozzi, OR, Vaidyanathan, G, Bigner, DD. Targeted α-Particle

Radiotherapy with 211At-labeled Monoclonal Antibodies. Nuclear Med Bio. 34(7):779-785, 2007.

IN PRESS


9

65. Gururangan, S, Frankel, W, Broaddus, R, Clendenning, M, Senter, L, McDonald, M, Eastwood, J,

Reardon, D, Vredneburgh, J, Quinn, J, Friedman, HS. Multi-focal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro-Oncol, In press, 2007.

66. Vredenburgh, JJ, Desjardins, A, Herndon, JE, Marcello, J, Reardon, DA, Quinn, JA, Rich, JN,

Sathornsumetee, S, Gururangan, S, Sampson, JH, Wagner, M, Bailey, L, Bigner, DD, Friedman, AH, Friedman, HS. Bevacizumab and Irinotecan: An Acitve Regimen Against Recurrent Glioblastoma Multiformed. J Clin Onc, in press, 2007.

67. Reardon, DA, Zalutsky, MR, Akabani, G, Coleman, RE, Friedman, AH, Herndon, JE, McLendon, RE, Pegram,

CN, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Boulton, A, Raynor, RH, Wong, TZ, Zhao, XG, Friedmanm, HS, Bigner, DD. A Pilot Study: 131I-Anti-Tenascin Monoclonal Antibody 81C6 to Deliver a 44 Gy Resection Cavity Boost, Neuro Oncol., In press, 2007.

68. Reardon, DA, Zalutsky, MR, Akabani, G, Coleman, RE, Friedman, AF, Herndon II, JE, McLendon, RE,

Pegram, CN, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Boulton, S, Raynor, RH, Wong, TZ, Zhao, X, Friedman, HS, Bigner, DD. A Pilot Study: 131I-Anti-Tenascin Monoclonal Antibody 81C6 to Deliver a 44 Gy Resection Cavity Boost. Neuro-Oncol. In press, 2007.

69. Michael R. Zalutsky, MR, Reardon, DR, Akabani, G, Coleman, RE, Friedman, AH, Friedman, HS,

Herndon, II, JE, McLendon, RE, Pegram, CN, Sampson, JH, Wong, TZ, Zhao, X, Bigner, DD,. First Clinical Experience with α-Emitting Astatine-211: Treatment of Recurrent Brain Tumor Patients with 211At-labeled Chimeric 81C6 Anti-Tenascin Monoclonal Antibody. J Neuro Med, In press, 2007.

70. Reardon, DA, Desjardins, A, Vredenburgh, JJ, Sathornsumetee, S, Rich, JN, Quinn, JA, Lagattuta, TF,

Egorin, MJ, Gururangan, S, McLendon, R, Herndon II, JE, Friedman, AH, Salvado, AJ, Friedman, HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma. Neuro-Oncol. In press, 2007.

Non-refereed publications:

1. Reardon DA, Friedman HS, Powell JB Jr, Gilbert M, Yung WK. Irinotecan: promising activity in the treatment of malignant glioma. Oncology (Huntingt), 17(5 Suppl 5):9-14, 2003.

2. Boskovitz A, Wikstrand CJ, Kuan C, Zalutsky MR, Reardon DA, Bigner DD. Monoclonal antibodies for

brain tumor treatment. Vaccines & antibodies. Expert Opin. Biol. Ther. 4(9):1453-71, 2004. 3. Reardon DA, Rich JN, Friedman HS. Combinatorial approaches using trageted therapeutics for patients

with malignant glioma. . 41st Annual Meeting. May 13-17, 2005. Orlando, FL. American Society of Clinical Oncology 2005 Educational Book 168-73, 2005.

4. Reardon DA. Targeted therapies for the treatment of malignant glioma. Sponsored by Health Science

Center for Continuing Medical Education. March 31, 2005.


10

5. Desjardins, A, Rich JN, Quinn, JA, Vredenburgh, J, Gururangan, S, Sathornsumetee, S, Reardon, DA, Friedman, AH, Bigner, DD, Friedman, HS. Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 10:2645-68, 2005.

3. Chapters in books:

1. Childhood Cancer: A Handbook from St. Jude Children’s Research Hospital: Chapter 5: The Genetics of Childhood Cancer; Steen RG and Mirro J (eds); Perseus Books, Cambridge, MA 2000.

2. Zalutsky, M.R., Reardon, D.A., Akabani, G., Friedman, A.H., Friedman, H.S., and Bigner, D.D.:

Targeted irradiation of brain tumours. In: Targeted Cancer Therapies. Bruland, Ø.S., and Flagstad, T., eds., University of Tromso Press, pp. 155-159, 2003.

3. Heimberger AB, Reardon, DA, Bigner, DD, Sampson, JH: Immunotherapy of Central Nervous System

Tumors. Brain Tumors. In: Contermporary Cancer Research: Brain Tumors. Francis Ali-Osman, DSC, eds, Humana Press, Totowa, New Jersey, pp. 323-342, 2005.

4. Ali-Osman F, Friedman, HS, Antoun GR, Reardon D, Bigner DD, Buolamwini JK: Rational Design and

Development of Targeted Brain Tumor Therapeutics. In: Comtemporary Cancer Research: Brain Tumor. Francis Ali-Osman, DSC. Eds, Humana Press, Totowa, New Jersey, pp. 359-381, 2005.

4. Books: (Indicate authors or editor.)

5. Non-authored publications:

6. Other:

a. Published scientific reviews (for mass distribution

b. Selected abstracts 1. Durham KS, Yeager AM, Reardon D, Kasper DT, May WS, Petit GR. Differential effects of bryostatin-

1 on the growth of myeloid leukemia and normal hematopoietic cells in Lewis X Brown Norway hybrid (LBN) rat. Blood 74 (Suppl 1): 70, 1989.

2. Hanson CA, Reardon DA, Roskos R, Sheldon S, Holbrook EA, Roth MS. The detection of leukemia-specific mRNA transcripts from archival glass slide appears in Philadelphia-chromosome (Ph+) positive pediatric leukemia patients by the polymerase chain reaction (PCR). Blood 76 (suppl 1): 278, 1990.

3. Hutchinson R, Fryer C, Krailo M, Davis PC, Nachman J, Reardon D, Collins D, Del Rowe J, Whalen T, Blair G, O’Brien R, Hayes D, Guepes M, Trigg M, Hammond D (Children’s Cancer Group). Comparison of MOPP/ABVD with ABVD/XRT for the treatment of advanced Hodgkin’s disease in children (CCG-521). Proc Am Soc Clin Oncol 11:340, 1992.

4. Reardon DA, Terry V, Roth M. Detection of clonal cell populations using a novel RNA polymerase chain reaction assay. Proc Am Assoc Cancer Res 33:1492, 1992.


11

5. Hutchinson R, Fryer C, Krailo M, Davis PC, Nachman J, Reardon D, Collins R, Del Rowe J, Whalen T, Blair G, O’Brien R, Hayes D, Guepes M, Trigg M, Hammond D (Children’s Cancer Group). Prognostic factor analysis in advanced Hodgkin’s disease: results of CG-521 trial. Med Ped Oncol 21:546 (A61), 1993.

6. Reardon DA, Waecker NJ, Grau K, Thompson-Bowers JE. Nosocomial infection rate of an inpatient pediatric unit as a function of total occupied bed days. Annual Infectious Diseases Society of America, San Francisco, CA, September 17-19, 1995. Clin Infect Dis 21:733 (A81), 1995.

7. Reardon D, Michalkiewicz E, Sublett J, Ragsdale S, Valentine M, Behm F, Li H, Boyett J, Heideman R, Kun L, Shapiro D, Look T. Characterization of the molecular abnormalities of childhood medulloblastoma using comparative genomic hybridzation. 7th International Symposium of Pediatric Neuro-Oncololgy, Washington, DC, May 15-18, 1996.

8. Reardon D, Gajjar A, Walter A, Boyett J, Li H, Thompson S, Jenkins J, Sanford R, Langston J, Broniscer A, Heideman R, Kun L. Pediatric thalamic gliomas: 10 year St. Jude Children’s Research Hospital experience. 7th International Symposium of Pediatric Neuro-Oncology, Washington, DC, May 15-18, 1996.

9. Gajjar A, Walter A, Reardon D, Thompson S, Li H, Langston J, Jenkins J, Muhlbauer M, Boyett J, Sanford R, Heideman R, Kun L. A retrospective comparison of standard dose radiation therapy (RT) alone versus combined modality therapy in patietns >4 years of age with newly diagnosed medulloblastoma. 7th International Symposium of Pediatric Neuro-Oncology, Washington, DC, May 15-18, 1996.

10. Gajjar A, Heidemen R, Walter A, Reardon D, Thompson S, Li H, Langston J, Jenkins J, Muhlbauer M, Sanford R, Boyett J, Kun L. A comparison of clinical risk features and outcome among patients <4 years vs. >4 years at diagnosis with medulloblastoma. 7th International Symposium of Pediatric Neuro-Oncology, Washington, DC, May 15-18, 1996.

11. Heideman R, Gajjar A, Walter A, Reardon D, Sanford R, Kun L. Advances in the treatment of childhood astrocytoma and medulloblastoma. Hong Kong International Cancer Congress and International EBV Symposium. November 1996.

12. Heideman R, Gajjar A, Walter A, Reardon D, Sanford R, Kun L. The use of chemotherapy in pediatric central nervous system tumors. Hong Kong International Cancer Congress and International EBV Symposium. November 1996.

13. Reardon D, Look A, Heideman R, Boyett J, Kun L. Extensive genomic abnormalities in medulloblastoma by CGH. 12th International Conference on Brain Tumor Research and Therapy. September 20-23, 1997. J Neuro-Oncol 35:132, 1997.

14. Reardon D, Entrekin E, Sublett J, Ragsdale S, Li H, Boyett J, Look A. Chromosome 6q loss is a recurrent abnormality in primary pediatric ependymoma. 8th International Symposium of Pediatric Neuro-Oncology, Rome, Italy, May 6-9, 1998.

15. Reardon D, Thompson S, Gajjar A, Walter A, Boyett J, Li H, Jenkins J, Sanford R, Langston J, Kun L, Heideman R. Prognostic factors among children with hypothalamic glial neoplasms include age at


12

diagnosis, extend of resection and histology. 8th International Symposium of Pediatric Neuro-Oncology, Rome, Italy, May 6-9, 1998.

16. Gajjar A, Langston J, Mulhern R, Yang J, Heideman R, Walter A, Thompson S, Reardon D, Taylor J, Jones D, Boyett J, Merchant T, Sanford R, Kun L. The central nervous system lacunes – a sequellae of treatment in pediatric brain tumor survivors. 8th International Symposium of Pediatric Neuro-Oncology, Rome, Italy, May 6-9, 1998.

17. Gailani M, Bukowski J, Karpen H, Reardon D. The role of the hedgehog signaling pathway in sporadic medulloblastoma. Society for Pediatric Research, May 1998.

18. Fouladi M, Heideman R, Kun L, Jenkins J, Walter A, Thompson S, Reardon D, Merchant T, Liu A, Boyett J, Gajjar A. Examination of cerebrospinal fluid from lumbar and ventriculoperitoneal shunt (VP) taps for detecting leptomeningeal disease (LMD) in pediatric brain tumor patients. Proceedings ASCO, Atlanta, GA, 1999.

19. Walter A, Gajjar A, Thompson S, Reardon D, Heideman R, Kun L. Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children’s Research Hospital. Proceedings ASCO, Atlanta, GA, 1999.

20. Reardon D, Santana V, Stewart C, Thompson S, Ma M, Furman W, Pratt C, Spunt C, Houghton P, Pharmacokinetically-topotecan (TPT) 5 days/week for 2 consecutive weeks and weekly vincristine (Ver) given to children with relapsed solid tumors. American Society of Pediatric Hematology/Oncology, Montreal, Canada, September 14-18, 1999.

21. Reardon D, Sublet J, Ragsdale S, Thompson S, Merchant T, Kun L, Jenkins J, Burger P. Multiple genomic amplifications including N-myc in a primary large-cell medulloblastoma. American Society of Pediatric Hematology/Oncology, Montreal, Canada, September 14-18, 1999.

22. Cohen KJ, Eberhart CG, Aronson LJ, Reardon DA, Allen JC, Rosenblum MK, Melham ER, Tihan T, Burger PC. Pediatric intramedullary spinal tumors with diffuse leptomeningeal spread. 9th International Symposium on Pediatric Neuro-Oncology, San Francisco, CA, June 11-14, 2000.

23. Quinn JA, Rich JN, Reardon DA, Sampson JH, Provenzale JM, McLendon RE, Edwards SD, Tourt-Uhlig SE, Gururangan S, Affronti ML, Stewart ES, Buchanan MW, Bigner DD, Stafford-Fox V, Zaknoen S, Haglund MM, Friedman AH, Friedman HS. Phase II Trial of Temodar for Progressive Low Grade Glioma. Presentation: American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Am. Assoc. Cancer Res. 42:652-2001.

24. Reardon DA, Akabani G, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wong TZ, Zalutsky MR, Bigner DD. Results of a Phase II Trial in the Treatment of Newly Diagnosed Patients with High Grade Glioma Treated with Iodine 131 Murine Anti-Tenasdin Monoclonal Antibody 81C6 via Surgically Created Resection Cavities. Presentation: 92nd Annual Meeting, American Association for Cancer Research, March 24-28, 2001, New Orleans, LA. Proc. Am. Assoc. Cancer Res. 42:700, 2001.

25. Affronti M, Reardon D, Allen D, Friedman A, Gururangan S, Herndon J, Houghton P, Jackson S, McLendon R, Quinn J, Rich J, Sampson J, Tourt-Uhlig S, Walker A, Bigner D, Friedman H. Phase I


13

Trial of Topotecan with BCNU in the Treatment of Adult Patients with Recurrent High Grade Glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:63a, 2001.

26. Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, Cokgor I, McLendon R, Quinn J, Rich J, Regalado L, Sampson J, Shafman T, Wong T, Zalutsky M, Bigner D. Outcome of Newly Diagnosed Patients with High-Grade Glioma Treated with Iodine-131 Murine Anti-Tenascin Monoclonal Antibody 81C6 via Surgically Created Resection Cavities in a Phase II Trial. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Onc. 20:54a, 2001.

27. Cavazos, C.M., Gururangan, S., Herndon, J., II, Tourt-Uhlig, S., Moghrabi, A., Rich, J.N., Quinn, J.A.,

Reardon, D., Friedman, A.H., and Friedman, H.S.: A Phase II study of low-dose carboplatin (CBDCA) chemotherapy in adults with progressive low-grade gliomas. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:63a, 2001.

28. Shafman T, Friedman H, Friedman A, Akabani J, Cokgor I, Herndon J, II, McLendon R, Quinn J, Reardon D, Rich J, Regalado L, Sampson J, Wong T, Zalutsky, Bigner D. Update of a Phase II Trial of Iodine-131-Labeled Anti-Tenascin Monoclonal Antibody Treatment of Patients with Recurrent Brain Tumors. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:67a, 2001.

29. Gururangan, S., Cavazos, C.M., Herndon, J.E., II, Longee, D.C., Bottom, K.S., Bruggers, C., Moghrabi,

A., Watral, M., Tourt-Uhlig, S., Reardon, D.A., and Friedman, H.S.: A Phase II study of low-dose carboplatin (CBDCA) in children with progressive low-grade gliomas. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:375a, 2001.

30. Rich J, Reardon D, Allen D, Affronti M, Carter J, Edwards S, Friedman A, Gururangan S, Herndon J, Jackson S, McLendon R, Quinn J, Tourt-Uhlig S, Sampson J, Bigner D, Stafford-Fox V, Zaknoen S, Friedman H. Phase I/II Trial of Gliadel Plus Temodar for Adult Patients with Recurrent High-Grade Glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:75b, 2001.

31. Tourt-Uhlig S, Quinn JA, Rich JN, Reardon DA, Sampson JH, Provenzale M, McLendon RE, Edwards S, Gururangan S, Affronti ML, Buchanan W, Jackson S, Allen D, Penne K, Lentz C, Bigner DD, Haglund M, Friedman AH, Avgeropoulos N, Korones D, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II Trial of Temozolomide (Temodar) in Patients with Progressive or Recurrent Low Grade Glioma. Presentation: American Society of Clinical Oncology, 37th Annual Meeting, May 12-15, 2001, San Francisco, CA. Proc. Am. Soc. Clin. Oncol. 20:76b, 2001.

32. Reardon, D, Akabani, G, Friedman, A, Friedman, H, Herndon, II, J, Cokgor, I, McLendon, R, Quinn, J, Rich, J, Regalado, L, Sampson, J, Shafman, T, Wong, T, Zalutsky, M, and Bigner, D. Phase II trial results of iodine-131 murine anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities among newly diagnosed patients with high-grade glioma. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology


14

[serial online], Doc. B141, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (Suppl 1):S34-35, 2001.

33. Reardon, D, Affronti, ML, Allen, D, Friedman, A, Herndon, J, Houghton, P., Jackson, S., McLendon, R., Quinn, J., Rich, J., Walker, A., Sampson, J., Bigner, D., and Friedman, H.: Results of a Phase I trial of Topotecan with BCNU for adult patients with recurrent high grade glioma. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B142, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (Suppl 1):S35, 2001.

34. Reardon, D, Edwards, S, Friedman, A, Herndon, J, McLendon, R, Quinn, J, Rich, J, Tourt-Uhlig, S, Sampson, J, Stafford-Fox, V, Zaknoen, S, Bigner, D, Friedman, H. Results of a Phase I/II trial of Gliadel plus Temodar for adult patients with recurrent high-grade glioma. Presentation: Fourteenth International Conference on Brain Tumor Research and Therapy, May 27-30, 2001, Asheville, NC. Neuro-Oncology [serial online], Doc. B143, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (Suppl 1):S35, 2001.

35. Reardon, D, Akabani, G, Friedman, A, Friedman, H, Herndon, J, McLendon, R, Quinn, J, Rich, J, Regalado, L, Sampson, J, Shafman, T, Wong, T, Bigner, D, Zalutsky, M. A Phase I study of Astatine-211 labeled human/murine chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities for patients with high grade gliomas. . Presentation: World Federation of Neuro-Oncology First Quadrennial Meeting and Society for Neuro-Oncology Sixth Annual Meeting, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. A362, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (4):365, 2001.

36. Reardon, D, Affronti, ML, Allen, D, Beason, R, Gururangan, S, Friedman, A, Herndon, J, Jackson, S, McLendon, R, Quinn, J, Rich, J, Sampson, J, Walker, A, Ziegler, K, Bigner, D, Friedman, H. A Phase II study of irinotecan plus BCNU for adults with high grade gliomas. Presentation: . Presentation: World Federation of Neuro-Oncology First Quadrennial Meeting and Society for Neuro-Oncology Sixth Annual Meeting, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. A362, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (4):365, 2001.

37. Reardon, D, Affronti, ML, Allen, D, Beason, R, Evans, B, Gururangan, S, Friedman, A, Jackson, S, McLendon R, Quinn, J, Rich, J, Sampson, J, Stafford-Fox, V, Ziegler, K, Bigner, D, Friedman, H. A Phase I study of CPT-11 plus temozolomide for adults with recurrent malignant glioma. Presentation. Presentation: World Federation of Neuro-Oncology First Quadrennial Meeting and Society for Neuro-Oncology Sixth Annual Meeting, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. A362, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (4):365, 2001.

38. Reardon, D, Sampson, J, Akabani, G, Archer, G, Coleman, R, Friedman, A, Friedman, H, Herndon, J, Kunwar, S, McLendon, R, Penne, K, Provenzale, J, Quinn, J, Rich, J, Marcus, S, Pastan, I, Bigner, D: A Phase I Study of intratumoral infusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated Form of the Pseudomonas Exotoxin (TP-38) for the Treatment of Malignant Brain Tumors. Presentation: World Federation of Neuro-Oncology First Quadrennial Meeting and Society for Neuro-Oncology Sixth Annual Meeting, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. A362, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (4):366, 2001.


15

39. Quinn, JA, Glantz, M, Petros, W, Rich, J, Sands, H, Tourt-Uhlig, S, Walker, A, Reardon, D, Gururangan, S, Sampson, J, Friedman, A, Colvin, OM, Friedman, H. Intrathecal Spartaject™ busulfan phase I trial for patients with neoplastic meningitis. Presentation: World Federation of Neuro-Oncology First Quadrennial Meeting and Society for Neuro-Oncology Sixth Annual Meeting, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. A362, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (4):364, 2001.

40. Friedman, H, Quinn, J, Reardon, D, Rich, J, Friedman, A, Sampson, J, Evans, B, Tourt-Uhlig, S, Stafford-Fox, V, Bigner, D, Zaknoen, S. Phase II treatment of adults with brain metastases with Temodar. Presentation: World Federation of Neuro-Oncology First Quadrennial Meeting and Society for Neuro-Oncology Sixth Annual Meeting, November 15-18, 2001, Washington, DC. Neuro-Oncology [serial online], Doc. A362, URL http://neuro-oncology.mc.duke.edu. Neuro-Oncology 3 (4):358, 2001.

41. Sampson, JH, Reardon, D, Akabani, G, Archer, G, Friedman, A, Friedman, H, Herndon, J, McLendon, R, Penne, K, Paolino, A, Tourt-Uhlig, S, Quinn, J, Rich, J, Williams, R, Marcus, S, Wang, Q-C, Pastan, I, Bigner, D. A Phase I study of intratumoral infusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the pseudomonas exotoxin (TP-38) for the treatment of malignant brain tumors. Abstract #3703. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:746, 2002.

42. Reardon, D, Akabani, G, Friedman, A, Friedman, H, Herndon, J, McLendon, R, Quinn, J, Rich, J, Penne, K, Sampson, J, Shafman, T, Wong, T, Zalutsky, M, Bigner, D. Phase I trial results: treatment of patients with newly diagnosed malignant gliomas using 131-iodine labeled human/murine chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities. Abstract #2440. Presentation: American Association for Cancer Research, 93rd Annual Meeting, April 6-10, 2002, San Francisco, CA. Proc. Am. Assoc. Cancer Res. 43:491, 2002.

43. Sampson, JH, Reardon, D, Akabani, G, Archer, G, Friedman, A, Friedman, H, Herndon, J, McLendon, R, Penne, K, Paolino, A, Tourt-Uhlig, S, Quinn, J, Rich, J, Williams, R, Marcus, S, Pastan, I, Bigner, DD. A phase I study of intratumoral infusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin (TP-38) for the treatment of malignant brain tumors. Presentation 1860: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:13b, 2002.

44. Affronti, ML, Reardon, D, Allen, D, Beason, R, Gururangan, S, Friedman, A, Herndon, J, Jackson, S, McLendon, R, Quinn, J, Rich, J, Sampson, J, Walker, A, Bigner, DD, Friedman, H. A phase II study of CPT-11 plus BCNU for adults with high grade glioma. Presentation 2091: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:70b, 2002.

45. Tourt-Uhlig, S, Reardon, D, Affronti, ML, Allen, D, Beason, R, Evans, B, Gururangan, S, Friedman, A, Jackson, S, McLendon, R, Quinn, J, Rich, J, Sampson, J, Stafford-Fox, V, Ziegler, K, Bigner, DD, Friedman, H. Treatment of adults with recurrent malignant glioma using temozolomide plus CPT-11: a phase I study. Presentation 2096: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:71b, 2002.

46. Friedman AH, Agarwal S, Evans B, Walker A, Tourt-Uhlig S, Reardon D, Affronti ML, Allen D, Beason R, Gururangan S, Jackson S, McLendon R, Quinn J, Rich J, Sampson J, Stafford-Fox V, Ziegler K,


16

Bigner DD. Novel Use of Gliadel for Gliomas. Presentation 2109/ American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL 21:74b, 2002.

47. Reardon, D, Akabani, G, Friedman, A, Friedman, H, Herndon II, J, Cokgor, I, McLendon, R, Quinn, J, Rich, J, Penne, K, Sampson, J, Shafman, T, Wong, T, Zalutsky, M, Bigner, DD. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody treatment of patients with newly diagnosed malignant brain tumors following external beam radiotherapy. Presentation 2113: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:75b, 2002.

48. Quinn, JA, Glantz, M, Petros, W, Rich, J, Sands, H, Tourt-Uhlig, S, Walker, A, Reardon, D, Gururangan, S, Sampson, J, Friedman, A, Colvin, OM, Friedman, H. Phase I trial of intrathecal Spartaject™ busulfan for patients with neoplastic meningitis. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:80a, 2002.

49. Friedman, AH, Agarwal, S, Evans, B, Walker, A, Tourt-Uhlig, S, Reardon, D, Affronti, ML, Allen, D, Beason, R, Gururangan, S, Jackson, S, McLendon, R, Quinn, J, Rich, J, Sampson, J, Stafford-Fox, V, Ziegler, K, Bigner, D, Friedman, H. Novel use of gliadel for gliomas. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:74b, 2002.

50. Friedman, HS, Pluda, J, Weingart, J, Brem, H, Evans, B, Petros, W, Rich, J, Tourt-Uhlig, S, Gururangan, S, Reardon, D, Sampson, J, Friedman, A, Provenzale, J, McLendon, R, Colvin, OM, Bigner, D, Dolan, E, Pegg, A, Moschel, R, Quinn, J. Phase I trial of temodar plus O6-benzylguanine in the treatment of patients with recurrent or progressive cerebral anaplastic gliomas. Presentation: American Society of Clinical Oncology, 38th Annual Meeting, May 18-21, 2002, Orlando, FL. 21:78a, 2002.

51. Reardon, D.: Anti-tenascin antibody (81c6) in radioimmunotherapy of human gliomas. Second International Congress on Monoclonal Antibodies in Cancer. Banff, Alberta, Canada, August 29 – September 1, 2002, oral presentation.

52. Reardon, D, Akabani, G, Friedman, A, Friedman, H, Herndon, J, McLendon, R, Quinn, J, Rich, J, Penne, K, Sampson, J, Shafman, T, Wong, T, Zalutsky, M, Bigner, D. Treatment of patients with newly diagnosed malignant gliomas using iodine 131-labeled human-mouse chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities: Phase I/II trial results. Presentation: Fifth Congress of the European Association of Neuro-Oncology, September 7-10, 2002, Florence, Italy.

53. Quinn, J, Pluda, J, Weingart, J, Brem, H, Petros, W, Evans, B, Rich, J, Tourt-Uhlig, S, Gururangan, S, Reardon, D, Sampson, J, Friedman, A, Provenzale, J, McLendon, R, Colvin, M, Bigner, D, Dolan, E, Pegg, A, Moschel, R, and Friedman, H. Phase I trial of Temodar plus O6-Benzylguanine in the treatment of patients with recurrent or progrssive cerebral anaplastic gliomas. Abstract 241. Society for Neuro-Oncology Seventh Annual Meeting, San Diego, CA, November 21-24, 2002. Neuro-Oncology 4:374, 2002.

54. Reardon, D, Friedman, H, Yung, W, Provenzale, J, Jackson, E, Leeds, N, Conrad, C, Walker, A, Henry, A, Huang, J, Laurent, D, Dugan, M. A phase I trial of Temodar plus PTK787/ZD222584 (PTK/ZK), a novel oral VEGF TK inhibitor, for patients with recurrent glioblastoma. Abstract 244. Society for Neuro-Oncology Seventh Annual Meeting, San Diego, CA, November 21-24, 2002, Neuro-Oncology 4:375, 2002.


17

55. Reardon, D, Sampson, J, Akabani, G, Archer, G, Coleman, R, Friedman, A, Friedman, H, Herndon, J, Kunwar, R, McLendon, R, Penne, K, Paolino, A, Quinn, J, Rich, J, Williams, R, Wong, T, Marcus, S, Bigner, D, Pastan, I. Preliminary phase I study results of a recombinant chimeric protein composed of transforming growth factor alpha (TGF)-α and a mutated form of the pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Abstract 246. Society for Neuro-Oncology Seventh Annual Meeting, San Diego, CA, November 21-24, 2002. Neuro-Oncology 4:376, 2002.

56. Reardon, D, Akabani, G, Friedman, A, Friedman, H, Herndon, J, McLendon, R, Quinn, J, Rich, J, Penne, K, Sampson, J, Shafman, T, Wong, T, Zalutsky, M, Bigner, D. Results of a phase I/II trial using iodine 131-labeled human–mouse chimeric antitenascin monoclonal antibody 81C6 via surgically created resection cavities in the treatment of patients with newly diagnosed malignant gliomas. Abstract 245. Society for Neuro-Oncology Seventh Annual Meeting, San Diego, CA, November 21-24, 2002. Neuro-Oncology 4:375, 2002.

57. Reardon, D., Affronti, M.L., Allen, D., Beason,R., Gururangan, S., Friedman A., Herndon, J, Jackson, S., McLendon, R., Quinn, J., Rich, J., Sampson, J., Walker, A., Ziegler, K., Bigner, D.D., and Friedman, H.: A phase II study of upfront CPT-11 plus BCNU for adults with newly diagnosed high grade glioma. Abstract 243. Society for Neuro-Oncology Seventh Annual Meeting, San Diego, CA, November 21-24, , 2002. Neuro-Oncology 4:375, 2002.

58. Reardon, D, Akabani, G, Herndon, J, Wong, T, Coleman, E, Friedman, H, Friedman, A, Zalutsky, M, Bigner, D. Radiolabeled anti-tenascin monoclonal antibody 81c6 administered into surgical resection cavities in the treatmen tof patients with malignant brain tumors. Keystone Symposia Meeting, Banff, Alberta, Canada, February 4-9, 2003.

59. Sampson, JH, Akabani, G, Archer, G, Berger, M, Coleman, RE, Friedman, A, Friedman, HS, Herndon, J,

Kunwar, S, Marcus, S, McLendon, R, Provenzale, J, Quinn, J, Reardon, D, Rich, J, Wong, T, Williams, R, Yuan, F, Zalutsky, M, Bigner, D, Pastan, I. Response and convection-enhanced delivery imaging results of a Phase I trial of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated Pseudomonas exotoxin termed PE-38 (TP-38) for the direct intracerebral treatment of malignant brain tumors. Abstract #4004. Presented at the AACR 94th Annual Meeting, July 11-14, 2003, Washington D.C. Proc. Am. Assoc. Cancer Res. 44:916, 2003.

60. Sampson, JH, Akabani, G, Archer, G, Berger, M, Coleman, RE, Friedman, A, Friedman, HS, Herndon, J, Kunwar, S, Marcus, S, McLendon, R, Provenzale, J, Quinn, J, Reardon, D, Rich, J, Wong, T, Williams, R, Yuan, F, Zalutsky, M, Bigner, D, Pastan, I. Response and convection-enhanced delivery imaging results of a Phase I trial of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated Pseudomonas exotoxin termed PE-38 (TP-38) for the direct intracerebral treatment of malignant brain tumors. Abstract #4004. Presented at the AACR 94th Annual Meeting, July 11-14, 2003, Washington D.C. Proc. Am. Assoc. Cancer Res. 44:916, 2003

61. Sampson, JH, Reardon, D, Akabani, G, Archer, G, Coleman, R, Friedman, A, Friedman, H, Herndon, J, Kunwar, S, McLendon, R, Penne, K, Paolino, A, Quinn, J, Rich, J, Williams, R, Marcus, S, Pastan, I, Bigner, D. Preliminary phase I study results of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Presentation, AANS Annual Meeting, April 26-May 1, 2003, San Diego, California, 2003.


18

62. Archer, G.E., Sampson, J.H., Friedman, H., Friedman, A., Reardon, D., Quinn, J., Paolino, A., and Bigner, D.D.: Immunologic monitoring of a dendritic cell based vaccine trial in glioma patients. Abstract #2000. Presentation, AACR 94th Annual Meeting, July 11-14, 2003, Washington, D.C. Proc. Am. Assoc. Cancer Res. 44:456, 2003.

63. Reardon, D, Akabani, G, Friedman, A, Friedman, H, Herndon, J, McLendon, R, Quinn, J, Rich, J, Penne, K, Sampson, J, Shafman, T, Vredenburgh, J, Wong, T, Zalutsky, M, Bigner, D. Phase I trial results using iodine 131-labeled human-mouse chimeric anti-tenascin monoclonal antibody 81C6 via surgically created resection cavities in the treatment of patients with malignant gliomas. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003. Neuro-Oncology 5:395, 2003.

64. Rich, JN, Peery, T, Reardon, D, Quinn, JA, Dancey, J, Wikstrand, C, Stenzel, TT, McLendon, RE, Friedman, A, Sampson, J, Bigner, DD, Friedman, HS. Phase I/II trial of ZD1839 (Iressa) in patients with first relapse glioblastoma. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003. Neuro-Oncology 5:396, 2003.

65. Rich, JN, Keir, ST, Wheeler, C, Reardon, DA, Bigner, DD, Friedman, HS. ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, inhibits central nervous system tumor growth following oral administration. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003. Neuro-Oncology 5:396, 2003

66. Sampson, JH, Akabani, G, Reardon, DA, Coleman, RE, Friedman, HS, Provenzale, J, Friedman, AH, Pedain, C, Brady, M, Raghavan, R, Pastan, I, Bigner, DD. Imaging and predicting the extensive intracerebral distribution of macromolecules after direct infusion. Presentation, Fifteenth International Conference on Brain Tumor Research and Therapy, May 24-27, 2003, Sorrento, Italy. Neuro-Oncology 5:397, 2003.

67. Rich, JR, Keir S, Goudar RK, Hjelmeland MD, Wheeler C, Reardon DA, Bigner DD, Friedman HS. ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits central nervous system tumor growth following oral administration. Abstract ET-40.Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003, Neuro-Oncology 5(ET-40):307, 2003.

68. Rich, JN, Peery, T, Reardon, D, Quinn, JA, Dancey, J, Wikstrand, C, Stenzel, TT, McLendon, RE, Friedman, A, Sampson, J, Bigner, DD, Friedman, HS. Phase I/II trial of ZD1839 (Iressa) in patients with first relapse glioblastoma. 15th International Conference on Brain Tumor Research, Sorrento, Italy, May 24-27, 2003. Neuro-Oncology 5:396, 2003.

69. Badruddoja, MA, Reardon, DA, Vredenburgh, J, Perry, TS, Quinn, JA, Rich, JN, Gururangan,,S, Friedman, HS. Low-grade glioma progressing as kluver-bucy syndrome. Abstract RA-02. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:336, 2003.

70. Badruddoja, MA, Peery, TS, Vredenburgh, J, Reardon, DR, Quinn, JA, Rich, JN, Gururangan, S, Friedman, HS. Fusarium pneumonia in a neutropenic patient after CPT-11 for Glioblastoma. Abstract TA-03. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:348, 2003.


19

71. Badruddoja MA, Reardon ,DA, Beason, R, Friedman A, Quinn, JA, Rich ,J, Sampson, J, Stafford-Fox, V, Bigner, DD, Friedman, HS. Phase I study of temozolomide plus irinotecan (CPT-11) in adults with recorrent malignant glioma. Abstract TA-04. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:348, 2003.

72. Quinn, J, Glantz, M, Petros, W, Rich, J, Sands, H, Tourt-Uhlig, S, Walker, A, Reardon, D, Gururangan, S, Vredenburgh, J, Sampson, J, Friedman, A, Colvin, OM, Friedman ,H. Phase I trial of intrathecal spartaject ™ busulfan for patients with neoplastic meningitis. Abstract TA-27. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:354, 2003.

73. Reardon, D, Affronti,,M, Allen, D, Baddrudoja, M, Beason, R, Friedman A, Gururangan, S, Jackson, S, Quinn, J, Rich, J, Sampson, J, Vredenburgh, J, Walker, A, Ziegler, K, Bigner, D, Friedman, H. A phase ii study of CPT-11 plus celecoxib for adults with recurrent malidnant glioma. Abstract TA-31. Presented at Society of Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:355, 2003.

74. Reardon, D, Akabani, G, Friedman, A, Friedman, H, Herndon, J, Shafman, T, Wong, T, Coleman, R, Zalutsky, M, Bigner, D. Phase II trial of iodine 131-labeled murine antitenascin monoclonal antibody 81C6 (M81C6) via surgically created resection cavities in the treatment of patients with recorrent malignant brain tumors. Abstract TA-32. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:355, 2003.

75. Reardon, D, Friedman H, Yung, W, Brada, M, Conrad, C, Provenzale, J, Jackson, E, Serajuddin, H, Laurent, D, Reitsma, D. Preliminary phase I trial results: PTK787/ZK222584 (PTK/ZK), an oral vegf tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Abstract TA-33. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:355, 2003.

76. Rich, JN, Peery, T, Reardon, DA, Quinn, JA, Van Duyn, L, Dancey, J, Wikstrand, C, Stenzel, T, McLendon, R, Herndon, J, Friedman, AH, Sampson, J, Bigner, DD, Friedman, HS. Phase I/II trial of the epidermal growth factor receptor small molecule inhibitor ZD1839 (gefitinib) in patients with first relapse glioblastoma. Abstract TA-34. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:356, 2003.

77. Quinn, J, Reardon, D, Rich, J, Gururangan, S, Vredenburgh, J, Friedman, A, McLendon, R, Tourt-Uhlig, S, Chen, C, Stafford-Fox, V, Coover, C, Friedman, H. Phase II treatment of adults with newly diagnosed , progressive or recurrent primary central newvous system lymphoma with temodar. Abstract TA-28. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:354, 2003.

78. Quinn, J, Bigner, D, Friedman, A, Herndon, J, McLendon, R, Provenzale, J, Rich, J, Reardon, D, Vredenburgh, J, Tourt-Uhlig, S, Walker, A, Stafford-Fox, V, Coover, C, Friedman, H. Abstract TA-29. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:354, 2003.

79. Rich, JR, Goudar, RK, Hjelmeland, MD, Keir, ST, Traxler, P, Lane, H, Reardon, DA, Bigner, DD, Friedman, HS. Combination of AEE788, an epidermal growth factor receptor/vascular endothelial


20

growth factor receptor 2 (VEGFR2) inhibitor, and RAD001, an inhibitor of the mammalian traget of rapamycin, inhibits glioblastoma tumor growth following oral administration. Abstract ET-39. Presented at Society for Neuro-Oncology Eighth Annual Meeting, Keystone, CO, November 13-16, 2003. Neuro-Oncology 5:307, 2003.

80. Conrad, C., Friedman, H., Reardon, D., Provenzale, J., Jackson, E., Serajuddin, H., Laurent, D., Chen, B., and Yung, W.K.A.: A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Abstract #1512. Presentation: ASCO Annual Meeting, 2004. Proc. Am. Soc. Clin. Oncol. 22:110S, 2004.

81. Yung, W, Friedman, H, Reardon, D, Provenzale, J, Jackson, E, Serajuddin, H, Laurent, D, Chen, B, Conrad, C. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Abstract #786P. Neuro-Onc, 15:207, 2004.

82. Reardon, D, Friedman, H, Yung, WKA, Brada, M, Conrad, C, Provenzale, J, Jackson, E, Serajuddin, H, Chen, B, Laurent, D. A phase I/II trial of PTK787/XK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Abstract #1513. Presentation: ASCO Annual Meeting, 2004. Proc. Am. Soc. Clin. Oncol. 22:110S, 2004.

83. Desjardins, A, Quinn, JA, Reardon, DA, Rich, JN, Vredenburgh, JJ, Efird, C, Friedman, HS. Phase II study of thalidomide and daily Cyclophosphamide for adults with malignant glioma. Abstract #1554. Presentation: ASCO Annual Meeting, 2004. Proc. Am. Soc. Clin. Oncol. 22:120S, 2004.

84. Badruddoja, MA, Reardon, DA, Akabani, G, Friedman, AH, Friedman, HS, Rich, JN, Quinn, JA, Penne, K, Vredenburgh, JJ, Bigner, DD. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. Abstract #1569. Presentation: ASCO Annual Meeting, 2004. Proc. Am. Soc. Clin. Oncol. 22:124S, 2004.

85. Reardon, DA, Akabani, G, Dowell, J, Friedman, A, Friedman, H, Herndon, J, McLendon, R, Quinn, J, Rich, J, Vredenburgh, J, Penne, K, Sampson, J, Shafman, T, Wong, T, Coleman, R, Zalutsky, M, Bigner, D. Results of a phase II trial with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 (m81C6) via surgically created resection cavities in the treatment of patients with recurrent malignant brain tumors. Abstract #5237. Presented at the AACR 95th Annual Meeting, March 27-31, 2004, Orlando, Florida. Proc. Am. Assoc. Cancer Res. 45:1208, 2004.

86. Archer, GE, Bigner, DD, Friedman, A, Friedman, HS, Penne, K, Lally-Batts, D, Paolino, A, Tourt-Uhlig, S, Reardon, D, Sampson, J. Dendritic cell vaccine for intracranial tumors I (DC VICTORI trial). Abstract IM-02. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:341, 2004.

87. Badruddoja, MA, Reardon, DA, Vredenburgh, JJ, Quinn, JA, Rich, JN, Desjardins, A, Friedman, A, Walker, A, Bailey, P, Jex, R, Friedman, HS. Phase II upfront CPT-11 plus celecoxib for adults with glioblastoma multiforme. Abstract TA-01. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:369, 2004.


21

88. Desjardins, A, Quinn, J, Reardon, D, Rich, J, Vredenburgh, J, Friedman, A, Tourt-Uhlig, S, Badruddoja, M, Efird, C, Friedman, HS. Phase II study of thalidomide and daily low-dose cyclophosphamide for adults with anaplastic gliomas. Abstract TA-16. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:373, 2004.

89. Desjardins, A, Reardon, D, Vredenburgh, J, Rich, J, Gururangan, S, Friedman, A, Sampson, J, Provenzale, J, McLendon, R, Herndon II, J, Badruddoja, M, Amara, J, Tourt-Uhlig, S, Newton, H, Friedman, HS, Quinn, JA. Phase I trial of adults with primary malignant glioma with irinotecan (CPT-11) plus temozolomide (Temodar). Abstract TA-17. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:373, 2004.

90. Quinn, JA, Desjardins, A, Reardon, D, Vredenburgh, J, Rich, J, Gururangan, S, Friedman, A, Sampson, J, Provenzale, J, McLendon, R, Herndon II, J, Dolan, ME, Badruddoja, M, Walker, A Tourt-Uhlig, S, Friedman, HS. Phase I trial of temozolomide (Temodar) plus irinotecan (CPT-11) plus O6-benzylguanine (O6-BG) in the treatment of recurrent or progressive cerebral anaplastic gliomas. Abstract TA-44. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:380, 2004.

91. Quinn, JA, Desjardins, A, Reardon, D, Vredenburgh, J, Rich, J, Gururangan, S, Friedman, A, Sampson, J, Provenzale, J, McLendon, R, Herndon, II, J, Dolan, ME, Badruddoja, M, Walker, A, Tourt-Uhlig, S, Friedman, HS. Phase II trial of temozolomide (Temodar) plus O6-benzylguanine (O6-BG) in the treatment of patients with temodar-resistant malignant glioma. Abstract TA-45. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:380, 2004.

92. Reardon, D, Akabani, G, Friedman, A, Friedman, HS, Herndon, J, McLendon, R, Quinn, J, Rich, J, Vredenburgh, J, Penne, K, Sampson, J, Gururangan, S, Shafman, T, Wong, T, Dowell, J, Dunn, R, Badruddoja, M, Desjardins, A, Affronti, M, Allen, D, Jackson, S, Zeigler, K, Silverman, S, Tourt-Uhlig, S, Coleman, R, Zalutsky, M, Bigner, DD. Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. Abstract TA-46. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:381, 2004.

93. Reardon, D, Friedman, A, Herndon, J, Quinn, J, Rich, J, Vredenburgh, J, Badruddoja, M, Desjardins, A, Sampson, J, Gururangan, S, Dowell, J, Affronti, M, Allen, D, Jackson, S, Zeigler, K, Silverman, S, Tourt-Uhlig, S, Silverman, S, Salvado, A, Nikolova, Z, Bigner, DD, Friedman, HS. Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. Abstract TA-47. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:381, 2004.

94. Reardon, D, Friedman, H, Brada, M, Conrad, C, Provenzale, J, Jackson, E, Serajuddin, H, Chen, B, Laurent, D, Yung, W. A phase I/II trial of PTK787/ZK 222584 (PTK/zK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme. Abstract 784O. Neuro-Oncology. 15:207, 2004.

95. Reardon, D, Friedman, HS, Brada, M, Conrad, C, Provenzale, J, Jackson, E, Serajuddin, H, Chen, B. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in


22

combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Abstract TA-48. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:381, 2004.

96. Sampson, JH, Friedman, AH, Reardon, DA, Friedman, HS, Provenzale, JM, Bigner, DD, Brady, M, Raghavan, R, Pedain, C, Archer, G, Lally-Batts, D, McGehee, S, Tourt-Uhlig, S, Grahn, A, Dul, JL, Croteau, D, Sherman, JW, and Puri, RK: Convection-enhanced delivery of Il13-PE38QQR in malignant glioma: Comparison of observed and predicted drug distribution. Abstract TA-49. Presented at Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004. Neuro-Oncology 6:381, 2004.

97. Vredenburgh, JJ, Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, Rich J, Zalutsky M, Bigner A. Results of a phase II study of 131 iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. Abstract #1510 Presentation. ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:116a, 2005.

98. Friedman, HS, Quinn, J, Rich, J, Vredenburgh, J, Desjardins, A, Sathornsumetee, S, Salvado, A, Nikolova Z, Bigner D, Reardon, D. Efficancy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. Abstract #1513. Presentation. ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:117s, 2005

99. Reardon, D, Cloughesy, T, Conrad, C, Prados, M, Xia, J, Mietiowski, W, Dugan, M, Mischel, P, Friedman, H, Yung, A. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Abstract #3063. Presentation. ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:207s, 2005.

100. Sathornsumetee, S, Reardon, DA, Quinn J, Rich, JN, Vredenburgh, JJ, Desjardins, A, Gururangan, S, Lyons, P, Salvado, A, Friedman, HS. A phase I dose escalation study of imatinib mesylate plus standard-dosed temozolmide in the treatment of patients with malignant glioma. Abstract #1540. Presentation. ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:124s, 2005.

101. Sathornsumetee, S, Batt, D, Kieran, M, Kier, S, Ramsey, T, Yusuff, N, Reardon, D, Bigner, D, Friedman, H, Rich, J. Targeting malignant gliomas with a low-molecular-weight Raf/vascular endothelial growth factor receptor inhibitor. Abstract 381. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):379, 2005.

102. Rich, JN, Keir, ST, Sathornsumetee, S, Reardon, DA, Bigner, DD, Friedman, HS. Imatinib mesylate (STI-571, Gleevec®) offers combinatorial benefit with temozolomide (Temodar®) against gliomas. Abstract #5979. Presented at the AACR 96th Annual Meeting, April 16-20, 2005, Anaheim, CA.

103. Rich JN, Reardon, DA, Quinn, JA, Vredenburgh, JJ, Desjardins, A, Sathornsumetee, S, Gururangan, S, Lyons, P, Bigner, DD, Friedman, HS. A phase I trial of gefitinib (ZD1839) plus repamycin for patients with recurrent malignant glioma. Abstract #1565. Presentation. ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:130s, 2005.


23

104. Reardon, DA, Quinn, J, Rich, J, Vredenburgh, J, Desjardins, A, Sathornsumetee, S, Salvado, A, Nikolova, Z, Bigner, D, Friedman, H. Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results. Abstract 35. Oral Poster Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):291, 2005.

105. Reardon, D., Akabani, G., Friedman, A., Friedman, H., McLendon, R., Quinn, J., Rich, J., Vredenburgh,

J., Zalutsky, M., and Bigner, D.: An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity. Abstract 117. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):311, 2005.

106. Reardon, A, Rich, J, Quinn, J, Vredenburgh, J, Desjardins, A, Sathornsumetee, S, Gururangan, S, Lyons, P, Bigner, D, Friedman, H. Phase 1 study results of gefitinib (IRESSA; ZD1839) plus rapamycin in the treatment of patients with recurrent malignant glioma. Abstract 119. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):312, 2005.

107. Badruddoja, MA, Penne, K, Desjardins, A, Reardon, AD, Rich, JN, Quinn, J, Sznol, M, Cahill, A, Friedman, HS, Vredenburgh, J. Phase II study of VNP40101M for adults with recurrent malignant glioma. Abstract #3128. Presentation: ASCO Annual Meeting 2005. Proc. Am. Soc. Clin. Oncol. 23:223s, 2005.

108. Desjardins, A, Vredenburgh, J, Badruddoja, M, Quinn, J, Reardon, D, Rich, J, Sathornsumetee, S, Penne, K, Bigner, D, Friedman, H. Phase II study of cloretazine for the treatment of adults with recurrent malignant glioma. Abstract 141. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):317, 2005.

109. Desjardins, A, Quinn, J, Reardon, D, Rich, J., Sathornsumetee, S, Vredenburgh, J, Walker, A, Tourt-Uhlig, S, Bigner, D, and Friedman, H. Temozolomide (TMZ) with O6-benzylguanine (BG) for TMZ-resistant malignant glioma: a phase 2 trial. Abstract 471. Presentation for the WFNO II/EANO VI meeting, May 5-8, 2005, Edinburgh, Scotland. Neuro-Oncol. 7(3):401, 2005.

110. Heimberger, AB, F. Hussain, S, Suki, D, Hess, K, Shi, W, Aldape, K, Crutcher, L, Gilbert, M, Sawaya, R, Archer, G, Smith, D, Friedman, H, Reardon, D, Herndon, JE, Friedman, A, Bigner, D, Sampson, JH. An Epidermal Growth Factor Receptor Variant III Peptide Vaccination is Highly Efficacious in Newly Diagnosed GBM Patients: Results of a Phase II Clinical Trial. April 25, Am Assoc Neuro Surg, 2006.

111. Reardon, DA, Wen, PY, Lyons, P, Rich, JN, Berk, L, Knowles, HL, Rivera, VM, Bedrosian, CL, Friedman, HS. A Phase I Trial of AP23573, a Novel mTOR Inhibitor, in Patients (Pts) with Recurrent Malignant Glioma. Abstract# A195. Poster Presentation at 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. November 14-18, 2006, Philadelphia, Pennsylvania. Proc. Am. Assoc. Cancer Res. 105, 2006.

112. Aldape, K, Cloughesy, T, Reardon, D, Conrad, C, Prados, M, Xia, J, Mietlowski, W, Huang, J, Dugan, M, Mischel, P, Friedman, H, Yung, A. Analyses of EGF and VEGF Signaling Pathways in Recurrent Glioblastoma Patients in a Phase I Study of Single-agent AEE788. Abstract# A260. Poster Presentation


24

at 2005 AACR-NCI-EORTC International Conference on Molecular Tagets and Cancer Therapeutics. Novermber 14-18, 2006, Philadelphia, Pennsylvania. Proc. Am. Assoc. Cancer Res. 122, 2006.

113. Desjardins, A, Herndon II, JE, Quinn, J, Rich, J, Sathornsumetee, S, Vredenburgh, JJ, Friedman, HS,

Reardon, D, Gururangan, S, Friedman, A. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. Abstract #1506. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):59a, 2006.

114. Reardon, D, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Sathornsumetee, S, Fururangan, S,

Egorin, MJ, Salvado, A, Friedman, HS. A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. Abstract #1580. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):77s, 2006.

115. Heimberger, AB, Hussain, SF, Aldape, K, Sawaya, R, Archer, GA, Friedman, H, Reardon, D, Friedman,

A, Bigner, D, Sampson, JH. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. Abstract #2529. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):107s, 2006.

116. Vredenburgh, JJ, Bohlin C, Reardon, DA, Desjardins, A, Quinn, J, Rich, J, Sathornsumetee, S, Marks,

LB, Friedman, AH, Friedman, HS. Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients. Abstract #1539. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(67s):67s, 2006.

117. Sathornsumetee, S, Reardon, DA, Quinn, JA, Rich, JN, Vredenburgh, JJ, Desjardins, A, Gururangan, S,

Egorin, M, Salvado, A, Friedman, HS. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. Abstract #1560. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):72s, 2006.

118. Quinn, JA, Vredenburgh, JJ, Rich, JN, Reardon, DA, Desjardins, A, Gururangan, S, Friedman, AH,

Lavin, K, Sathornsumetee, S, Threatt, S, Friedman, HS. Phase II Trial of Gliadel plus O6-bezylguanine (o6-BG) for patients with recurrent glioblastoma multiforme. Abstract #1568. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):74s, 2006.

119. Desjardins, A, Reardon, DA, Quinn, JA, Rich, JN, Vredenburgh, JJ, Sathornsumetee, S, Salvado, A,

Friedman, HS. Phase II trial of imatinib mesylate and hydroxyurea for grade II malignant gliomas Abstract #1573. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):76s, 2006.

120. Heery, CR, Desjardins, A, Quinn, JA, Rich, JN, Gururangan, S, Vredenburgh, JJ, Friedman, AH,

Reardon, DA, Friedman, HS. Acute Toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. Abstract #11504. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):593ss, 2006.

121. Kirkpatrick, J, Desjardins, A, Vredenburgh, JJ, Quinn, JA, Rich JN, Sathornsumetee, S, Gururangan, S,

Friedman, AH, Friedman, HS, Reardon, DA. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases. Abstract #11522. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):594s, 2006.


25

122. Jones LW, Guill B, Keir ST, Carter K, Friedman HS, Bigner DD, Reardon MD. Exercise interest and

preferences among a population-based cohort of patients diagnosed with primary brain cancer. Poster accepted at the 9th International Congress of Behavioral Medicine, Bangkok, Thailand (2006, December).

123. Paldino, MJ, Barboriak, DP, Wong, TZ, Reardon, DA, Friedman, HS. Correlation of registered

quantitiative 18-F-FDG-PET and contrast-enhanced MR imaging fingins with survival in patients undergoing intracacitary radiation therapy for high grade glioma. RSNA meeting, December, 2006.

124. Vredenburgh, JJ, Desjardins, A, Herndon II, JE, Quinn, J, Rich, J, Sathornsumetee, S, Friedman, HS,

Reardon, D, Gururangan, S, Friedman, A. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. Abstract #1506. Presentation. ASCO Annual Meeting 2006. Proc. Am. Soc. Clin. Oncol. 24(18s):59s, 2006.

125. Reardon, DA, Cloughesy, T, Rich, JN, Yung, W , Dilea, C, Mietlowski, W, Yung, L, Chen, W, Lai, A,

Conrad, C. A phase I study of combination therapy with AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, and RAD001, a mTOR inhibitor in recurrent GBM patients. Presentation. EORTC-NCI-AACR meeting on November 7th in Prague, 2006.

126. Goli, KJ, Desjardins, A, Herndon, JE, Herndon II, JE, Rich, JN, Reardon, DA, Quinn, JA,

Sathornsumetee, S, Bota, DA, Friedman, HS, Vredenburgh, JJ. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):75s, 2007.

127. Samspon, JH, Aldape, KD, Gilbert, MR, Hassenbursch, SJ, Sawaya, R, Schmitting, B, Archer, GE,

Mitchell, D, Bigner, DD, Reardon, DA, Heimberger, AB. Temozolomide as a vaccine adjuvant in GBM. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):80s, 2007.

128. Sathornsumetee, S, Rich, JN, Vredenburgh, JJ, Desjardins, A, Quinn, JA, Gururangan, S, Egorin, MJ,

Salvado, AJ, friedman, HS, Reardon, DA. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):81s, 2007.

129. Sathornsumetee, S, Rich, JN, Vredenburgh, JJ, Desjardins, A, Quinn, JA, Gururangan, S, Egorin, MJ,

Salvado, AJ, Friedman, HS, Reardon, DA. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):81s, 2007.

130. Desjardins, A, Barboriak, DP, Herndon II, JE, Reardon, DA, Quinn, JA, Rich, JN, Sathornsumetee, S,

Gururangan, S, Friedman, HS, Vredenburgh, JJ,. Dynamic contrast-enhancement magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):82s, 2007.

131. Quinn, JA, Vredenburgh, JJ, Rich, JN, Reardon, DA, Desjardins, A, Gururangan, S, Friedman, AH,

Carter, JH, Threatt, S, Friedman, HS,. Phase II trial of Gliadel plus O6-benzylguanic (O6-BG) for patients with recurrent glioblastoma multiforme. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):84s, 2007.


26

132. Bota, DA, Desjardins, A, Quinn, JA, Rich, JN, Vredenburgh, JJ, Sathornsumetee, S, Goli, K, Salvado, A,

Friedman, HS, Reardon, DS. Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):88s, 2007.

133. Affronti, ML, Day, JM, Herndon II, JE, Rich, JN, Quinn, JA, Reardon, DA, Vredenburgh, JJ,

Desjardins, A, McLendon, RE, Friedman, HS,. Radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy for glioblastoma (GBM) patients. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):92s, 2007.

134. Rich, JN, Affronti, ML, Day, JM, Herndon II, JE, Quinn, JA, Reardon, DA, Vredenburgh, JJ, Desjardins,

A, Friedman, HS,. Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU)wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):92s, 2007.

135. Bohlin, CW, Reardon, DA, Desjardins, A, Quinn, JA, Rich, JN, Bota, DA, Goli, K, Friedman, HS,

Vredenburgh, JJ,. Tinzaparin prophylaxis is brain tumor patients. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):605s, 2007.

136. Jones, L, lAffronti, ML, Bohlin, CW, Herndon II, JE, Quinn, JA, Reardon, DA, Rich, JN, Friedman, HS,

Vredenburgh, JJ,. Prevalence of osteoporosis in glioma patients on enzyme induring anticonvulsants (EIAC) and/or glucocorticoids. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):709s, 2007.

137. Vredenburgh, JJ, Bohlin CH, Reardon, DA, Desjardins, A, Quinn, JA, Rich, JN, Bota, DA, Goli, KJ,

Friedman, HS, Allen, DH,. Pilot study of Dronabinol for adult patients with primary malignant gliomas. ASCO Annual Meeting 2007. Proc. Am. Soc. Clin. Oncol. 25(18s):715s, 2007.

138. Mitchell, D, Heimberger, A, Friedman, H, Reardon, D, Vredenburgh, J, Gilbert, M, Friedman, A,

Sawaya, R, Aldape, K, Bigner, D, Sampson, J. Temozolomide therapies induces and increase in regulatory T-cells without abrogating a specific tumor antigen immune response in patients with GBM. Abstract #IM-29. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):509, 2007

139. Mitchell, D, Archer, G, Bigner, D, Friedman, A, Friedman, H, Reardon, D, Vredenburgh, J, Herndon, J,

McLendon, R, Sampson, J,. RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma. Abstract #IM-31 Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):509, 2007

140. Sathornsumetee, S, Vredenburgh, J, Rich, J, Desjardins, A, Quinn, J, Bota, D, Goli, K, Mathe, A,

Gururangan, S, Friedman, a, Friedman, Reardon, D,. Phase II trial of Bevacizumad and Erlotinib in recurrent glioblastoma multiforme (GBM). Abstract #MA-06. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):516, 2007

141. Reardon, D, Groves, M, Wen, P, Nabors, L, Mikkelsen, T, Rosenfeld, S, Harris, D, DeMarini, D, Suttle,

B, Arumugham, T, Hodge, J, Lager, J,. A phase II trial of Lapatinib and Pazopanib for patients with


27

recurrent glioblastoma multiforme (GBM). Abstract #MA-07. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):516, 2007

142. Reardon, D, Fink, K, Nabors, L, Cloughesy, T, O’Neill, A, Schiff, D, Raizer, J, Krueger, S, Picard, M,

Mikkelsen, T,. An update of the phase II a trial of Cliengitide (EMD121974 single-agent therapy in patients with recurrent glioblastoma: EMD 121974-009. Abstract #MA-08. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):517, 2007.

143. Bota, D, Desjardins, a, Rich, J, Vredenburgh, J, Quinn, J, Sathornsumetee, S, Goli, K, Salvado, A,

Friedman, H, Reardon, D,. Update on phase II trial of Imatinib Mesylate (Gleevec) and Hydroxyurea for adults with recurrent/progressive low-grade glioma. Abstract #MA-16. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):519, 2007

144. Goli, K, Bota, D, Desjardins, A, Rich, J, Vredenburgh, J, Quinn, J, Sathornsumetee, S, Salvado, A,

Friedman, H, Reardon, D,. A phase II trial of Imatinib Mesylate (Gleevec) and Hydroxyurea for adults with recurrent/progressive meningioma. Abstract #MA-18. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):519, 2007.

145. Desjardins, A, Sathornsumetee, S, Reardon, D, Krishna, G, Bota, D, Quinn, J, Rich, J, Gururangan, S,

Threatt, S, Friedman, A, Friedman, H, Vredengurgh, J,. A phase I trial of the addition of the farnesyl transferase inhibitor SCH 66336 to Temozolomide for patients with grade 3 or 4 malignant gliomas. Abstract #MA-35. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):524, 2007

146. Gururangan, S, Krauser, J, Watral, M, Driscoll, T, Larrier, N, Fuchs, H, Reardon, D, Vredenburgh, J,

Quinn, J, Desjardins, A, Rich, J, Friedman, H,. Evaluation of the efficacy of high-dose chemotherapy (HDC) + autologous stem cell rescue (ASCR) +/- radiotherapy (RT) or standard salvage therapy in children with recurrent medulloblastoma (MBL). Abstract #MP-15. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):540, 2007.

147. Affronti, ML, Bohlin, C, Bronson, K, Jones, L, Herndon, J, Quinn, J, Reardon, D, Desjardins, A, Rich, J,

Friedman, H, Vredenburgh, J,. Phase II trial of Zoledronic Acid (ZA) for bone loss prevention in glioma patients. Abstract #QL-10. Twelfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):566, 2007.

148. Desjardins, A, Barboriak, D, Herndon II, JE, Reardon, D, Quinn, J, Rich, J, Sathornsumetee, S,

Friedman, H, Vredenburgh, J,. Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (GBM) patients treated with Bevacizumab (BEV) and Irinotecan (CPT-11). T Abstract #RA-03. welfth Annual Meeting of the Society for Neuro-Oncology, Dallas, TX, November 15-18, 2007. Neuro-Oncology 9(4):573, 2007.

c: Editorials, position, and background papers Consultant appointments:


28

Cancer; American Cancer Society Editorial Advisory Board

February 15, 2006 - February 15, 2009

Journal of Neuro-Oncology Editorial Board

January 31, 2005 – present

Professional awards and special recognitions:

Sydney Gellis Pediatrics Award, Tufts University School of Medicine

1986

United States Air Force Achievement Award

1995

United States Navy Commendation Award, 995 Rookie of the Year, Department of Pediatrics, Maine Medical Center

1999

R. Wayne Rundles Award for Excellence in Cancer Research, Comprehensive Cancer Center, Duke University Medical Center

2007

Organizations and participation:

American Association of Cancer Research

1992-present

Pediatric Oncology Group, Associate Member

1993-present

American Society of Clinical Oncology

1997-present

American Society of Pediatric Hematology-Oncology

1997-present

Society for Neuro-Oncology

1998-present

Society for Pediatric Research 2006-present

CURRICULUM VITAE Date Prepared: October 9, 2007 · CURRICULUM VITAE Date Prepared: October 9, 2007 Name : David Reardon, MD Primary academic appointment: Department of Pediatrics

Documents